STOK: רווח נקי למניה ב-12 החודשים האחרונים stoketherapeutics.com

Stoke Therapeutics (STOK) is fighting for leadership in the RNA therapy segment, facing intense pressure from industry behemoths. Business resilience relies on the success of epilepsy drug trials and strict liquidity control. Diversification into ophthalmology reduces regulatory risks. The current trailing twelve-month earnings per share illustrates profitability, where -3.79 describes the current status of the metric.

The reliability of oligonucleotide supply chains for Stoke Therapeutics (STOK) directly impacts operational efficiency, which is reflected in the trailing 12-month net income per share on the GURU.Markets platform. This indicator measures the portion of profit attributable to a single security over a rolling year, allowing investors to assess the real return on capital relative to the WACC to determine the investment premium.